Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin
extended-release 500 mg tablets to Bayer's Cipro® XR 500 mg tablets following a single, oral
500 mg (1 x 500 mg) dose administered under fasting conditions.